FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3161054897> ?p ?o ?g. }

• W3161054897 abstract "Abstract Background Spinal cord motor neurons (MNs) from human iPS cells (iPSCs) have wide applications in disease modeling and therapeutic development for amyotrophic lateral sclerosis (ALS) and other MN-associated neurodegenerative diseases. We need highly efficient MN differentiation strategies for generating iPSC-derived disease models that closely recapitulate the genetic and phenotypic complexity of ALS. An important application of these models is to understand molecular mechanisms of action of FDA-approved ALS drugs that only show modest clinical efficacy. Novel mechanistic insights will help us design optimal therapeutic strategies together with predictive biomarkers to achieve better efficacy. Methods We induce efficient MN differentiation from iPSCs in 4 days using synthetic mRNAs coding two transcription factors (Ngn2 and Olig2) with phosphosite modification. These MNs after extensive characterization were applied in electrophysiological and neurotoxicity assays as well as transcriptomic analysis, to study the neuroprotective effect and molecular mechanisms of edaravone, an FDA-approved drug for ALS, for improving its clinical efficacy. Results We generate highly pure and functional mRNA-induced MNs (miMNs) from normal and ALS iPSCs, as well as embryonic stem cells. Edaravone alleviates H 2 O 2 -induced neurotoxicity and electrophysiological dysfunction in miMNs, demonstrating its neuroprotective effect that was also found in the glutamate-induced miMN neurotoxicity model. Guided by the transcriptomic analysis, we show a previously unrecognized effect of edaravone to induce the GDNF receptor RET and the GDNF/RET neurotrophic signaling in vitro and in vivo , suggesting a clinically translatable strategy to activate this key neuroprotective signaling. Notably, edaravone can replace required neurotrophic factors (BDNF and GDNF) to support long-term miMN survival and maturation, further supporting the neurotrophic function of edaravone-activated signaling. Furthermore, we show that edaravone and GDNF combined treatment more effectively protects miMNs from H 2 O 2 -induced neurotoxicity than single treatment, suggesting a potential combination strategy for ALS treatment. Conclusions This study provides methodology to facilitate iPSC differentiation and disease modeling. Our discoveries will facilitate the development of optimal edaravone-based therapies for ALS and potentially other neurodegenerative diseases. Graphic Abstract" @default.
• W3161054897 created "2021-05-24" @default.
• W3161054897 creator A5001729142 @default.
• W3161054897 creator A5014319544 @default.
• W3161054897 creator A5024411319 @default.
• W3161054897 creator A5029794800 @default.
• W3161054897 creator A5035672227 @default.
• W3161054897 creator A5038791884 @default.
• W3161054897 creator A5053188913 @default.
• W3161054897 creator A5053942296 @default.
• W3161054897 creator A5073177891 @default.
• W3161054897 creator A5073521470 @default.
• W3161054897 creator A5080005941 @default.
• W3161054897 creator A5084988077 @default.
• W3161054897 creator A5087765283 @default.
• W3161054897 date "2021-05-10" @default.
• W3161054897 modified "2023-10-15" @default.
• W3161054897 title "Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells" @default.
• W3161054897 cites W1523782066 @default.
• W3161054897 cites W1931706129 @default.
• W3161054897 cites W1966374880 @default.
• W3161054897 cites W1967600860 @default.
• W3161054897 cites W1968047722 @default.
• W3161054897 cites W1970581324 @default.
• W3161054897 cites W1970762906 @default.
• W3161054897 cites W1971208141 @default.
• W3161054897 cites W1975203903 @default.
• W3161054897 cites W1977374662 @default.
• W3161054897 cites W1984305664 @default.
• W3161054897 cites W1991107962 @default.
• W3161054897 cites W1993024959 @default.
• W3161054897 cites W2016961314 @default.
• W3161054897 cites W2022923808 @default.
• W3161054897 cites W2026095435 @default.
• W3161054897 cites W2026129060 @default.
• W3161054897 cites W2031135204 @default.
• W3161054897 cites W2040027262 @default.
• W3161054897 cites W2060406470 @default.
• W3161054897 cites W2077144621 @default.
• W3161054897 cites W2085165928 @default.
• W3161054897 cites W2091746433 @default.
• W3161054897 cites W2094603776 @default.
• W3161054897 cites W2098597036 @default.
• W3161054897 cites W2104005232 @default.
• W3161054897 cites W2107018762 @default.
• W3161054897 cites W2114104545 @default.
• W3161054897 cites W2138596308 @default.
• W3161054897 cites W2144993965 @default.
• W3161054897 cites W2155069534 @default.
• W3161054897 cites W2167141411 @default.
• W3161054897 cites W2173508366 @default.
• W3161054897 cites W2317226401 @default.
• W3161054897 cites W2580950245 @default.
• W3161054897 cites W2588226816 @default.
• W3161054897 cites W2616124858 @default.
• W3161054897 cites W2751591443 @default.
• W3161054897 cites W2760524820 @default.
• W3161054897 cites W2766949700 @default.
• W3161054897 cites W2802796971 @default.
• W3161054897 cites W2807099927 @default.
• W3161054897 cites W2898966044 @default.
• W3161054897 cites W2903898378 @default.
• W3161054897 cites W2908621307 @default.
• W3161054897 cites W2964849163 @default.
• W3161054897 cites W2985919985 @default.
• W3161054897 cites W2991360048 @default.
• W3161054897 cites W3062645889 @default.
• W3161054897 cites W3087046884 @default.
• W3161054897 cites W4252979096 @default.
• W3161054897 doi "https://doi.org/10.1101/2021.05.09.443325" @default.
• W3161054897 hasPublicationYear "2021" @default.
• W3161054897 type Work @default.
• W3161054897 sameAs 3161054897 @default.
• W3161054897 citedByCount "0" @default.
• W3161054897 crossrefType "posted-content" @default.
• W3161054897 hasAuthorship W3161054897A5001729142 @default.
• W3161054897 hasAuthorship W3161054897A5014319544 @default.
• W3161054897 hasAuthorship W3161054897A5024411319 @default.
• W3161054897 hasAuthorship W3161054897A5029794800 @default.
• W3161054897 hasAuthorship W3161054897A5035672227 @default.
• W3161054897 hasAuthorship W3161054897A5038791884 @default.
• W3161054897 hasAuthorship W3161054897A5053188913 @default.
• W3161054897 hasAuthorship W3161054897A5053942296 @default.
• W3161054897 hasAuthorship W3161054897A5073177891 @default.
• W3161054897 hasAuthorship W3161054897A5073521470 @default.
• W3161054897 hasAuthorship W3161054897A5080005941 @default.
• W3161054897 hasAuthorship W3161054897A5084988077 @default.
• W3161054897 hasAuthorship W3161054897A5087765283 @default.
• W3161054897 hasBestOaLocation W31610548971 @default.
• W3161054897 hasConcept C104317684 @default.
• W3161054897 hasConcept C107459253 @default.
• W3161054897 hasConcept C126322002 @default.
• W3161054897 hasConcept C145103041 @default.
• W3161054897 hasConcept C150194340 @default.
• W3161054897 hasConcept C160539049 @default.
• W3161054897 hasConcept C162317418 @default.
• W3161054897 hasConcept C169760540 @default.
• W3161054897 hasConcept C170493617 @default.
• W3161054897 hasConcept C185856081 @default.
• W3161054897 hasConcept C25498285 @default.

• next